Nĩ maũndũ meva matonya kũtuma mũndũ awaa kanza ya mavũi?
Ũkunĩkĩli wĩonany'a kana mũndũ eethĩwa na ũwau wa kanza ya mavũi, no aemwe nĩ kũeka kũya na kũnyw'a sikala.
Ũwau wa kanza ya mavũi nĩ ũwau wĩ vinya kũiitwa na wĩthĩawa ũilyĩ ta ũwau wa kũkua ĩvinda ĩasa.
Tũsamũ tũu no tũtw'ĩke tumo na tũivika isionĩ ingĩ sya mwĩĩ, na ũu ũituma mũndũ ethĩwa na mathĩna angĩ.
Ve maũndũ maingĩ matonya kũtuma mũndũ ethĩwa na kanza ya mavũi. Maũndũ amwe nĩ ta ũwau wa mũsyawa, maũndũ ala mũndũ ũkwĩka e vakuvĩ na vala ũĩ, na mwĩkalĩle ũla wĩthĩawa naw'o.
Ve ũndũ ũngĩ ũtonya kũtuma tũsamũ tũeka kwĩana na kũa.
Andũ amwe nĩmatonya kwĩthĩwa makwatiwe nĩ mathĩna asu nũndũ wa kwĩthĩwa me vakuvĩ na syĩndũ imwe itonya kũtuma mũndũ awaa kanza ta syũki ya sikala, syũki yĩtawa radon, asbestos, na nzeve nthũku.
Ũwau wa kanza ya mavũi (lung cancer) no ũvathanw'e kwa mĩthemba ĩlĩ.
Andũ amwe methĩawa na ũwau wa kanza ya mavũi (lung cancer) me na ũwau ũngĩ wĩtawa lymphoma, na ũwau ũsu no ũtume mũndũ awaa na ayĩthĩwa na mathĩna angĩ.
O na ĩngĩ, ũkunĩkĩli ũla wĩkĩtwe wonanĩtye kana mũndũ no akwatwe nĩ ũwau ũsu eethĩwa na ũwau wa kanza.
Tũla twĩndũ tũnini tũla twĩthĩawa na kanza nĩtũtonya kũsiĩĩa mũvĩa wa mwĩĩ ndũkasũvĩe nĩ mowau, na ũu ũituma twĩthĩwa tũtonya kwĩana na kwĩnyaĩĩka tũte kũsiĩĩwa.
O na ĩngĩ, ũndũ tũsamũ tũu tũmbĩtwe no ũtume tũendeea kwĩana na tũiendeea kũthambĩa.
Ũkunĩkĩli ũla wĩkĩtwe ĩũlũ wa ũndũ kanza ya mavũi yĩthĩawa yĩilyĩ wonanasya kana nĩ vinya mũno mũndũ kũiitwa na ayĩendeea nesa.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Ũtao:']
["Kĩsese kĩĩ kĩseũvĩtw'e kwondũ wa kũmanyĩsya na kũtetheesya andũ, ĩndĩ ti kũnengane motao ma ũiiti kana ũtethyo ũngĩ."]
['Ũvoo ũla wĩ vo ndwaĩle kũtũmĩwa kũĩkĩĩthya kana mũndũ e na ũwau mũna, na ala mekwenda ũtao wa ũiiti maĩle kũneena na ndakĩtalĩ.']
["Kwa ngelekany'o, ĩla mũndũ wakũlya ĩkũlyo yĩ na namba, no amanye kana mũndũ ũsu e na ũwau mũna."]
['Kĩla ĩvinda neena na ndakĩtalĩ waku kana mũndũ ũngĩ ũsomeete maũndũ ma ũiiti. Ndũkaatate kũlea kana kũkua ĩvinda ũimũkũlya ũtao aĩ nũndũ wa maũndũ amwe wasoma Kĩsesenĩ kĩĩ. Ethĩwa wĩona ta wĩ na thĩna wa mĩtũkĩ, neena na namba ya 911 kana ũthi sivitalĩ ya mĩtũkĩ ĩla yĩ vakuvĩ.']
['Ũtao:']
['The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) nĩyaĩtye kana ala me na ũthasyo wa kumĩthya syĩndũ ila syĩ Indanetinĩ nĩmaĩle kũtata ũndũ matonya nĩ kana maĩkĩĩthye kana syĩndũ ila mekumĩthya nĩsyavĩnga mĩao ya nthĩ ya Amelika.']
['Ethĩwa wĩ na mũĩkĩĩo kana ũvoo ũla wĩ kĩsesenĩ kitũ kana nthĩnĩ wa syĩndũ ila tumasya nũvĩtĩsye mĩao yaku, no ũtũtũmĩe valũa ũũtwĩĩte kana no ũtũsiĩĩe tũikamĩsome.']
["Mĩao ya DMCA yaĩtye kana no nginya ũvoo ũla ũũtũmĩa kũtũtavya kana ve kĩndũ kĩna kĩnavĩnga mĩao ya kumĩthya syĩndũ wĩthĩwe na ũvoo ũũ: (1) ũvoo ĩũlũ wa syĩndũ ila iwetetwe kana nĩsyo ivĩngĩĩsiwe nĩ mĩao ĩsu; (2) ũvoo ĩũlũ wa syĩndũ ila iwetetwe kana nĩsyo ivĩngĩĩsiwe nĩ mĩao ĩsu na ũvoo ũtonya kũtũtetheesya kũmanya vala syĩndũ isu syĩ; (3) ũndũ ũtonya kũtũtavya ũndũ ũtonya kũtũtavya ũndũ ũtonya kũũkũlya, ta vala wĩkalaa, namba yaku ya simũ, na valũa waku wa simũ; (4) ũĩkĩĩthyo ũkwonany'a kana wĩ na mũĩkĩĩo kana syĩndũ ila iwetetwe vau iyĩtĩkĩlĩtw'e nĩ ũla wĩ na ũthasyo wa kũseũvya syĩndũ, kana nĩ mũũngamĩi wasyo, kana nĩ mĩao ĩngĩ."]
["(5) ũĩkĩĩthyo kuma kwaku, ũla ũandĩkĩte ũikĩa ũkũsĩ ũte wa w'o, kana ũvoo ũla wĩ nthĩnĩ wa livoti nĩ wa w'o na kana wĩ na ũkũmũ wa kũũngamĩa maũndũ ala mawetwa nĩ ũla ũkũũmĩw'a;"]
['Na (6) saii ya mwene syĩndũ kana mũndũ ũla ũnengetwe ũkũmũ wa kwĩka maũndũ kwondũ wake.']
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
